The influence of nimodipine and vasopressors on outcome in patients with delayed cerebral ischemia after spontaneous subarachnoid hemorrhage.

OBJECTIVEDelayed cerebral ischemia (DCI) is a major factor contributing to the inferior outcome of patients with spontaneous subarachnoid hemorrhage (SAH). Nimodipine and induced hypertension using vasopressors are an integral part of standard therapy. Consequences of the opposite effect of nimodipine and vasopressors on blood pressure on patient outcome remain unclear. The authors report the detailed general characteristics and influence of nimodipine and vasopressors on outcome in patients with SAH.METHODSThe authors performed a 2-center, retrospective, clinical database analysis of 732 SAH patients treated between 2008 and 2016. Demographic and clinical data such as age, sex, World Federation of Neurosurgical Societies (WFNS) grade, BMI, Fisher grade, history of arterial hypertension and smoking, aneurysm location, C-reactive protein (CRP) level, and detailed dosage of vasopressors and nimodipine during the treatment period were evaluated. Clinical outcome was analyzed using the modified Rankin Scale (mRS) 6 months after treatment. Univariate and multivariate regression analyses were performed. Additionally, mean arterial pressure (MAP), age, nimodipine, and vasopressor dose cutoff were evaluated with regard to outcome. The level of significance was set at ≤ 0.05.RESULTSFollow-up was assessed for 397 patients, 260 (65.5%) of whom achieved a good outcome (defined as an mRS score of 0-3). Univariate and multivariate analyses confirmed that nimodipine (p = 0.049), age (p = 0.049), and CRP level (p = 0.002) are independent predictors of good outcome. WFNS grade, Fisher score, hypertension, initial hydrocephalus, and total vasopressor dose showed significant influence on outcome in univariate analysis, and patient sex, smoking status, BMI, and MAP showed no significant association with outcome. A subgroup analysis of patients with milder initial SAH (WFNS grades I-III) revealed that initial hydrocephalus (p = 0.003) and CRP levels (p = 0.001) had significant influence on further outcome. When evaluating only patients with WFNS grade IV or V, age, CRP level (p = 0.011), vasopressor dose (p = 0.030), and nimodipine dose (p = 0.049) were independent predictors of patient outcome. Patients with an MAP < 93 mm Hg, a nimodipine cutoff dose of 241.8 mg, and cutoff total vasopressor dose of 523 mg had better outcomes.CONCLUSIONSAccording to the authors' results, higher doses of vasopressors can safely provide a situation in which the maximum dose of nimodipine could be administered. Cutoff values of the total vasopressor dose were more than 3 times higher in patients with severe SAH (WFNS grade IV or V), while the nimodipine cutoff remained similar in patients with mild and severe SAH. Hence, it seems encouraging that a maximum nimodipine dosage can be achieved despite the need for a higher vasopressor dose in patients with SAH.

[1]  C. Wirtz,et al.  The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia—continuous selective intracarotid nimodipine therapy in awake patients without sedation , 2019, Neurosurgical Review.

[2]  M. Schuhmann,et al.  Effect of Intra-Arterial and Intravenous Nimodipine Therapy of Cerebral Vasospasm After Subarachnoid Hemorrhage on Cerebrovascular Reactivity and Oxygenation. , 2017, World neurosurgery.

[3]  Justin M. Moore,et al.  Safety and Efficacy of Noncompliant Balloon Angioplasty for the Treatment of Subarachnoid Hemorrhage-Induced Vasospasm: A Multicenter Study. , 2017, World neurosurgery.

[4]  S. Mayer,et al.  Management of delayed cerebral ischemia after subarachnoid hemorrhage , 2016, Critical Care.

[5]  P. Vajkoczy,et al.  Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage , 2016, Neurocritical Care.

[6]  M. Harrigan,et al.  Vasospasm on transcranial Doppler is predictive of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. , 2016, Journal of neurosurgery.

[7]  J. Bartek,et al.  Intra-arterial nimodipine for cerebral vasospasm after subarachnoid haemorrhage: Influence on clinical course and predictors of clinical outcome , 2016, The neuroradiology journal.

[8]  K. Budohoski,et al.  Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial , 2015, Neurosurgery.

[9]  K. Schaller,et al.  Monitoring in Neurointensive Care – The Challenge to Detect Delayed Cerebral Ischemia in High-Grade Aneurysmal SAH , 2014, Front. Neurol..

[10]  S. Mehta,et al.  Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation. , 2014, The Cochrane database of systematic reviews.

[11]  G. Pradilla,et al.  Inflammation, Vasospasm, and Brain Injury after Subarachnoid Hemorrhage , 2014, BioMed research international.

[12]  R. Spetzler,et al.  Subarachnoid hemorrhage and outcome. Response. , 2013, Journal of neurosurgery.

[13]  R. Macdonald.  Subarachnoid hemorrhage and outcome. , 2013, Journal of neurosurgery.

[14]  R. Spetzler,et al.  Time course of recovery following poor-grade SAH: the incidence of delayed improvement and implications for SAH outcome study design. , 2013, Journal of neurosurgery.

[15]  Michael Forsting,et al.  European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage , 2013, Cerebrovascular Diseases.

[16]  B. Schmitz,et al.  The prognostic reliability of the Glasgow coma score in traumatic brain injuries: evaluation of MRI data , 2013, European Journal of Trauma and Emergency Surgery.

[17]  T. Schweizer,et al.  Mini-Mental State Examination versus Montreal Cognitive Assessment: Rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage , 2012, Journal of the Neurological Sciences.

[18]  G. Harlow,et al.  A Protocol of No Sedation for Critically Ill Patients Receiving Mechanical Ventilation: A Randomised Trial , 2011 .

[19]  Joseph P Broderick,et al.  Definition of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group , 2010, Stroke.

[20]  C. Lumenta,et al.  Continuous Selective Intraarterial Infusion of Nimodipine for Therapy of Refractory Cerebral Vasospasm , 2010, Neurocritical care.

[21]  R. Birgander,et al.  The Fisher grading correlated to outcome in patients with subarachnoid haemorrhage , 2009, British journal of neurosurgery.

[22]  A. Algra,et al.  Validation of a Prognostic Subarachnoid Hemorrhage Grading Scale Derived Directly From the Glasgow Coma Scale , 2008, Stroke.

[23]  C. R. Ingram,et al.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. , 1983, The New England journal of medicine.

[24]  G. Luijckx,et al.  Prediction of outcome after subarachnoid hemorrhage: timing of clinical assessment. , 2017, Journal of neurosurgery.

[25]  C. Drake,et al.  Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. , 1988, Journal of neurosurgery.